Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis.

Eastell R et al.

NCBI PubMed Central · Papers · License: Open Access

distributed systems architecture

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 170711
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.